Amgen Inc. (NASDAQ:AMGN) reported a 9% increase in total revenues to $9.2 billion in fiscal Q2 2025 compared to Q2 2024. GAAP EPS rose 92% to $2.65 due to higher revenues. Analysts have a median price target of $276.39 for AMGN, implying a 12.16% upside potential.

Vamil Divan from Guggenheim maintains a Hold rating on Amgen Inc. (NASDAQ:AMGN) with a price target of $288.00. Raymond James started coverage with a Market Perform rating. The firm noted the significant valuation of MariTide, positioning it as a niche player in the obesity market.

Amgen Inc. (NASDAQ:AMGN) is a biotech company focusing on human therapeutics, particularly in complex cancer areas with unmet needs. While AMGN shows potential, some believe other AI stocks offer better upside with less downside risk. Investors can explore a free report on the best short-term AI stock.

For more stock insights, check out “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now” on Insider Monkey. Disclosure: None.

Read more at Yahoo Finance: What Do Analysts Think About Amgen Inc. (AMGN)?